Gastrointestinal Disease
Conditions
Brief summary
The investigators will conducted a hospital-based cohort study in our 15-year experience with DA aimed at investigating the long-term outcomes of the patients with DA, along with analyzing the impact of the tumor characteristics, operations and adjuvant therapy on survival outcomes.
Detailed description
Numerous meta-analyses and systematic reviews have delved into the treatment of DA, yet the majority of the studies retrospective, single-center, and small sample size series, particularly in China. To bridge this knowledge gap, the investigators will conduct a hospital-based cohort study designed to investigate the long-term survival outcomes of the participants with the non-ampulla duodenal adenocarcinoma, and the effects of tumor characteristics, surgery, and adjuvant therapy on survival outcomes.
Interventions
PROCEDURERadical operation and perioperative therapy
Surgical intervention, particularly radical excision, was performed for each patient, including the extent of resection and lymph node dissection. Information on adjuvant therapies, such as chemotherapy and radiotherapy, was also recorded, specifying the regimens and durations.
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
(1) histologically confirmed non-ampulla DA;
Exclusion criteria
1. had other gastrointestinal cancer; 2. had incomplete medical records, or lost follow-up shortly after diagnosis; 3. refused clinical data collection.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Median overall survival time | 2009.10-2023.06 | Median survival is the time it takes half of the individuals in a given study population to reach or exceed a particular end event, calculated from the time an event occurred. Median survival is a statistical index describing the distribution of survival time. |
| 3-year overall survival rate | 2009.10-2023.06 | Three-year survival rate, also known as survival rate, refers to the number of patients with a disease who are still alive at the end of three years of follow-up as a percentage of the number of cases observed |
| 5-year overall survival rate | 2009.10-2023.06 | Five-year survival rate, also known as survival rate, refers to the number of patients with a disease who are still alive at the end of five years of follow-up as a percentage of the number of cases observed |
Contacts
Primary ContactHao Liu, MD, PhD
Outcome results
None listed